# Advancement in Scaffold-Based 3D Cell Culture Models for Osteosarcoma Drug Screening

## TL;DR

This review discusses how 3D cell culture models, especially scaffold-based systems, better mimic the tumor environment for osteosarcoma drug screening compared to traditional 2D methods.

## Contribution

The paper provides a systematic review of scaffold-based 3D models for osteosarcoma, highlighting their advantages and challenges in drug discovery.

## Key findings

- Scaffold-based 3D models better replicate the tumor microenvironment than 2D systems.
- These models improve the study of tumor-stroma interactions and drug resistance.
- Technical challenges remain in optimizing scaffolds and using patient-derived cells.

## Abstract

Osteosarcoma (OS), an extremely aggressive bone cancer
that primarily
occurs in children and teenagers, continues to pose critical clinical
challenges due to its high propensity for metastasis, resistance to
conventional therapies, and lack of specific biomarkers for early
detection. Despite advances in surgical techniques and chemotherapeutic
regimens, patient outcomes remain suboptimal, predominantly because
conventional two-dimensional (2D) cell culture systems do not accurately
mimic the intricate tumor microenvironment (TME), which often results
in limited success when translating preclinical results to clinical
success. In response to the shortcomings, the field has shifted toward
three-dimensional (3D) culture systems, which more accurately mimic
the spatial, mechanical, and biochemical characteristics of native
OS TME. This review systematically examines the evolution and current
state of 3D OS models, with a particular focus on scaffold-based systems.
These models, utilizing biomimetic scaffolds provide enhanced platforms
for studying tumor–stroma interactions, drug responses, and
chemoresistance. It also briefs the use of scaffold-free spheroid
models, which, despite their utility in replicating certain aspects
of tumor heterogeneity and cell–cell interactions, are limited
in their ability to fully emulate the in vivo microenvironment.
The review further discusses technical and translational hurdles,
such as optimizing scaffold properties and integrating patient-derived
cells, which must be addressed to realize the full potential of 3D
models in personalized medicine and drug discovery. The significant
advancement of scaffold-based 3D OS models offers a more physiologically
relevant platforms to bridge the gap between experimental research
and clinical application in chemotherapy.